<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">VMJ</journal-id>
<journal-id journal-id-type="hwp">spvmj</journal-id>
<journal-id journal-id-type="nlm-ta">Vasc Med</journal-id>
<journal-title>Vascular Medicine</journal-title>
<issn pub-type="ppub">1358-863X</issn>
<issn pub-type="epub">1477-0377</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1358863X11422584</article-id>
<article-id pub-id-type="publisher-id">10.1177_1358863X11422584</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Severe case and literature review of primary erythromelalgia: Novel <italic>SCN9A</italic> gene mutation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Skeik</surname><given-names>Nedaa</given-names></name>
<xref ref-type="aff" rid="aff1-1358863X11422584">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rooke</surname><given-names>Thom W</given-names></name>
<xref ref-type="aff" rid="aff1-1358863X11422584">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Davis</surname><given-names>Mark Denis P</given-names></name>
<xref ref-type="aff" rid="aff2-1358863X11422584">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Davis</surname><given-names>Dawn Marie R</given-names></name>
<xref ref-type="aff" rid="aff2-1358863X11422584">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kalsi</surname><given-names>Henna</given-names></name>
<xref ref-type="aff" rid="aff1-1358863X11422584">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kurth</surname><given-names>Ingo</given-names></name>
<xref ref-type="aff" rid="aff3-1358863X11422584">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Richardson</surname><given-names>Randal C</given-names></name>
<xref ref-type="aff" rid="aff4-1358863X11422584">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-1358863X11422584"><label>1</label>Vascular Medicine, Mayo Clinic, Rochester, MN, USA</aff>
<aff id="aff2-1358863X11422584"><label>2</label> Dermatology, Mayo Clinic, Rochester, MN, USA</aff>
<aff id="aff3-1358863X11422584"><label>3</label>Institute of Human Genetics, University Hospital Jena, Jena, Germany</aff>
<aff id="aff4-1358863X11422584"><label>4</label>Seattle Children’s B-5552 – Neurology, Seattle, WA, USA</aff>
<author-notes>
<corresp id="corresp1-1358863X11422584">Nedaa Skeik, Vascular Medicine Mayo Clinic Rochester, MN USA Email: <email>nskeik@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>17</volume>
<issue>1</issue>
<fpage>44</fpage>
<lpage>49</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Erythromelalgia is a rare clinical syndrome characterized by intermittent heat, redness, swelling and pain more commonly affecting the lower extremities. Symptoms are mostly aggravated by warmth and are eased by a cold temperature. In some cases, symptoms can be very severe and disabling. Erythromelalgia can be classified as either familial or sporadic, with the familial form inherited in an autosomal dominant manner. Recently, there has been a lot of progress in studying Na(v)1.7 sodium channels (expressed mostly in the sympathetic and nociceptive small-diameter sensory neurons of the dorsal root ganglion) and different mutations affecting the encoding <italic>SCN9A</italic> gene that leads to channelopathies responsible for some disorders, including primary erythromelalgia. We present a severe case of progressive primary erythromelalgia caused by a new de novo heterozygous missense mutation (c.2623C&gt;G) of the <italic>SCN9A</italic> gene which substitutes glutamine 875 by glutamic acid (p.Q875E). To our knowledge, this mutation has not been previously reported in the literature. We also provided a short literature review about erythromelalgia and Na(v) sodium channelopathies.</p>
</abstract>
<kwd-group>
<kwd>erythromelalgia</kwd>
<kwd>genetic mutations</kwd>
<kwd>sodium channelopathy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1358863X11422584" sec-type="cases">
<title>Case report</title>
<p>A 15-year-old female presented with a 13-year history of chronic intermittent painful skin redness and swelling of both feet and lower legs.</p>
<p>Her problem began when she started to walk. She had difficulty with, and avoided walking on rough textures and warm surfaces. She also cried when rough textured clothing was placed on the lower legs and feet. At the age of 4, the patient started to have frequent episodes of pain in the lower legs and feet with associated erythema, edema and warmth. Symptoms were present more often during the day and were aggravated by warm temperatures. She found symptomatic relief by immersing her feet in cold water. There were no other reported skin abnormalities or complaints, including joint pains, or constitutional symptoms including weight loss, fever, chills or fatigue. Her family history was negative for similar symptoms or vascular disorders.</p>
<p>For the subsequent 9 years, the patient had continued to have similar symptoms intermittently that did not affect her daily activities, school performance, or function. She was later diagnosed with hypothyroidism that was easily controlled with thyroid hormone supplement. Her exam was otherwise unremarkable with the exception of her small stature, placed on the fourth and 37th percentiles respectively for height and weight. The patient was diagnosed with growth hormone deficiency. IGF-1 values were low at 218 ng/ml (range: 228–957). She underwent growth hormone stimulation testing with clonidine, which showed her peak growth hormone response was 0.5 ng/ml (normal peak is greater than 10). A sustained trial of growth hormone replacement was not done at the family’s preference.</p>
<p>At the age of 13 years, the patient started to have intermittent blood pressure elevations that were worse at the times of her symptoms (highest systolic around 180). She used to receive intravenous nitroprusside that seemed to alleviate her skin symptoms. Her secondary hypertension work-up revealed normal electrolyte panels, urinalysis, renal ultrasound, and cardiac echocardiograms. However, during painful crises, plasma free total metanephrine (350 pg/ml; ref. range: &lt; 206) and plasma free normetanephrine (324 pg/ml; ref. range: &lt; 149) were noted to be increased. As part of work-up for neuroblastoma, CTs and MRIs of the abdomen, pelvis, and chest, MAG3 renograms, and I-123 MIBG scans were sequentially performed over an 8-year time period and were normal. Our presumption is that her periodic hypertension and mildly elevated metanephrines/normetanephrines were related to pain, although sufficient pain control could not be obtained to perform baseline testing when symptom-free. She was continued on oral phenoxybenzamine that was discontinued a few months later upon spontaneous improvement of her blood pressure.</p>
<p>In the past year (as she started puberty), her symptoms escalated in frequency and severity, evolving into constant erythema and warmth of the lower extremities with associated pain (<xref ref-type="fig" rid="fig1-1358863X11422584">Figure 1</xref>). Over the last few months the skin erythema vacillated to a dark blue discoloration. Symptoms were aggravated more by exertion, stress, weight-bearing and gravity dependency. She spent most of her time immersing her feet in cold water or exposing them to a fan. She could not wear socks or shoes, or cover her feet or legs. Her symptoms started to affect her activities of daily living and her school performance and attendance.</p>
<fig id="fig1-1358863X11422584" position="float">
<label>Figure 1.</label>
<caption>
<p>(A) / (B) Severe erythema and swelling of the lower extremities.</p>
</caption>
<graphic xlink:href="10.1177_1358863X11422584-fig1.tif"/></fig>
<p>Laboratory evaluation of the patient was performed at the initiation of symptoms in early childhood, including enzyme testing for Fabry’s disease and autoimmune and inflammatory arthritides markers, and was found to be negative. Her most recent laboratory work revealed normal values: WBC 4.5 × 10<sup><xref ref-type="bibr" rid="bibr9-1358863X11422584">9</xref></sup>/l, Hgb 13.6 g/dl, PLT 269 × 10<sup><xref ref-type="bibr" rid="bibr9-1358863X11422584">9</xref></sup>/l, ESR 23 mm/h, CRP &lt; 3 mg/dl, Na 141 mmol/l, K 4.7 mmol/l, creatinine 0.7 mg/dl, and TSH 3.6 mIU/l. There was slight elevation of Ca (10.5 mg/dl) and ALT (47 U/l). Lipid profile, iron studies and urinalysis were normal. Direct immunofluorescence of a skin biopsy was negative and H&amp;E of the specimen showed a subcorneal non-specific inflammation.</p>
<p>The chest X-ray, ECG, ECHO and pulmonary function tests were normal. Autonomic reflex screen testing including heart rate responses and quantitative sudomotor axon reflex test (QSART) revealed evidence of generalized postganglionic sudomotor and mild adrenergic vasomotor dysfunction likely consistent with diffuse small fiber neuropathy. Thermoregulatory sweat testing revealed generalized anhydrosis. EMG showed no evidence of large fiber neuropathy. Baseline lower extremities physiologic arterial studies revealed normal Doppler signals, increased temperature of the toes (but not exceeding core temperature), increased laser signals from a few digits and normal transcutaneous oxygen pressure tracing (TCPO<sub>2</sub>). With symptoms, she had similar findings with the exception of significantly decreased TCPO<sub>2</sub> on the left foot.</p>
<p>Genetic testing revealed a heterozygous missense mutation p.Q875E (c.2623C&gt;G) of the <italic>SCN9A</italic> gene (NM_002977.2), which substitutes glutamine 875 by glutamic acid and which has not been previously described in patients with erythromelalgia (<xref ref-type="fig" rid="fig2-1358863X11422584">Figure 2</xref>). The patient’s healthy parents and sibling were tested for the mutation and found to be normal, suggesting a novel de novo mutation. Of note, the residue at position 875 of the protein is highly conserved throughout evolution.</p>
<fig id="fig2-1358863X11422584" position="float">
<label>Figure 2.</label>
<caption>
<p>Sequence electropherogram of the heterozygous missense mutation p.Q875E (c.2623C&gt;G) of the <italic>SCN9A</italic> gene.</p>
</caption>
<graphic xlink:href="10.1177_1358863X11422584-fig2.tif"/></fig>
<p>Based on her clinical presentation and extensive work up, the patient was diagnosed with primary erythromelalgia. She had failed many therapies including aspirin, atenolol, systemic and topical lidocaine and steroids, clonazepam, narcotics, homeopathic therapies, acupuncture, TENS unit, and a re-trial of nitroprusside. Clonidine has helped some of the bedtime symptoms. She was started later on gabapentin, and topical amitriptyline-ketamine-Vanicream™ with some symptom relief.</p>
</sec>
<sec id="section2-1358863X11422584" sec-type="discussion">
<title>Discussion</title>
<p>Erythromelalgia, or Mitchell’s disease, was named by and after Weir Mitchell in 1878 from <italic>erythro</italic> (red), <italic>melos</italic> (extremity), and <italic>algos</italic> (pain).<sup><xref ref-type="bibr" rid="bibr1-1358863X11422584">1</xref></sup> Graves had described the disease symptoms of hot and painful legs earlier, in 1834.<sup><xref ref-type="bibr" rid="bibr2-1358863X11422584">2</xref></sup> Other names used in the literature included acromelalgia from <italic>acro</italic> (tip end or extremity), erythralgia, erythermalgia from <italic>therme</italic> (heat), erythermomelalgia, and erythroprosopalgia from <italic>prosopon</italic> (face).<sup><xref ref-type="bibr" rid="bibr3-1358863X11422584">3</xref>,<xref ref-type="bibr" rid="bibr4-1358863X11422584">4</xref></sup> Erythromelalgia is the most commonly used name to describe a rare clinical syndrome characterized by intermittent heat, redness, swelling and pain more commonly affecting the lower extremities that can be exacerbated by warming, exercise and dependence on legs, and relieved by cooling and elevation.<sup><xref ref-type="bibr" rid="bibr5-1358863X11422584">5</xref></sup></p>
<p>The pain is usually described as burning or piercing and sometimes can be very severe and disabling. Symptoms are usually intermittent but can be constant with changing intensity. It usually involves the lower extremities, occasionally affecting the hands and very rarely the ears and face.<sup><xref ref-type="bibr" rid="bibr6-1358863X11422584">6</xref></sup> Symptoms are more common in the summer and can be exacerbated by heat, ambulation, physical activity, sitting, leg dependence, or wearing shoes or gloves.<sup><xref ref-type="bibr" rid="bibr7-1358863X11422584">7</xref></sup> On the other hand, a cool temperature may alleviate symptoms and in some cases abort an episode. Symptoms tend to lessen with cooling of the extremities by immersion in ice or cold water; exposure to air current, such as by a fan; or elevation and uncovering the affected areas.<sup><xref ref-type="bibr" rid="bibr8-1358863X11422584">8</xref></sup></p>
<p>The incidence of the disease is very rare. A mean incidence of 1.3 per 100,000 was reported in persons living in Olmsted County, MN, USA in 2009. Women are slightly more affected than men.<sup><xref ref-type="bibr" rid="bibr9-1358863X11422584">9</xref></sup> Erythromelalgia can occur as a primary or secondary disorder. Primary erythromelalgia is mostly caused by mutation of the voltage-gated sodium channel α-subunit gene <italic>SCN9A</italic>. It can be classified as either familial or sporadic, with the familial form inherited in an autosomal dominant manner. Both of these may be further classified as either juvenile or adult onset. Juvenile onset occurs prior to age 20 years and frequently prior to age 10.<sup><xref ref-type="bibr" rid="bibr10-1358863X11422584">10</xref>,<xref ref-type="bibr" rid="bibr11-1358863X11422584">11</xref></sup> Reported secondary causes of erythromelalgia may include some myeloproliferative diseases, blood dyscrasias, drugs, infections, malignancies, connective tissue and autoimmune diseases, cellular storage diseases, neuropathies, and some ingested materials (<xref ref-type="table" rid="table1-1358863X11422584">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref></sup></p>
<table-wrap id="table1-1358863X11422584" position="float">
<label>Table 1.</label>
<caption>
<p>Reported causes of secondary erythromelalgia<sup>12</sup></p>
</caption>
<graphic alternate-form-of="table1-1358863X11422584" xlink:href="10.1177_1358863X11422584-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td><bold>Myeloproliferative diseases and blood disorders</bold></td>
</tr>
<tr>
<td> Essential thrombocythemia</td>
</tr>
<tr>
<td> Polycythemia vera</td>
</tr>
<tr>
<td> Myelodysplastic syndrome</td>
</tr>
<tr>
<td> Pernicious anemia</td>
</tr>
<tr>
<td> Thrombotic and immunologic thrombocytopenic purpuras</td>
</tr>
<tr>
<td><bold>Drugs</bold></td>
</tr>
<tr>
<td> Cyclosporine</td>
</tr>
<tr>
<td> Verapamil</td>
</tr>
<tr>
<td> Nicardipine</td>
</tr>
<tr>
<td> Nifedipine</td>
</tr>
<tr>
<td> Norephedrine</td>
</tr>
<tr>
<td> Bromocriptine and pergolide</td>
</tr>
<tr>
<td><bold>Infectious diseases</bold></td>
</tr>
<tr>
<td> HIV</td>
</tr>
<tr>
<td> Hepatitis B vaccine</td>
</tr>
<tr>
<td> Influenza vaccine</td>
</tr>
<tr>
<td> Infectious mononucleosis</td>
</tr>
<tr>
<td> Pox virus</td>
</tr>
<tr>
<td><bold>Connective tissue diseases</bold></td>
</tr>
<tr>
<td> SLE</td>
</tr>
<tr>
<td> Vasculitis</td>
</tr>
<tr>
<td><bold>Neuropathic</bold></td>
</tr>
<tr>
<td> Diabetic neuropathy Peripheral neuropathies</td>
</tr>
<tr>
<td> Neurofibromatosis</td>
</tr>
<tr>
<td> Riley–Day syndrome</td>
</tr>
<tr>
<td> Multiple sclerosis</td>
</tr>
<tr>
<td><bold>Neoplastic</bold></td>
</tr>
<tr>
<td> Paraneoplastic syndrome</td>
</tr>
<tr>
<td> Astrocytoma</td>
</tr>
<tr>
<td> Malignant thymoma</td>
</tr>
<tr>
<td><bold>Others</bold></td>
</tr>
<tr>
<td> Mushroom ingestion</td>
</tr>
<tr>
<td> Mercury poisoning</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Although the exact pathophysiology remains unknown, it seems to be different in the two types.<sup><xref ref-type="bibr" rid="bibr13-1358863X11422584">13</xref></sup> At the molecular level, primary (inherited) erythromelalgia is an autosomal dominant disorder caused by gain-of-function mutations in the <italic>SCN9A</italic> gene encoding the Na(v)1.7 sodium channel expressed mostly in the sympathetic and nociceptive small-diameter sensory neurons of the dorsal root ganglion that leads to altered function.<sup><xref ref-type="bibr" rid="bibr14-1358863X11422584">14</xref></sup> The Na(v)1.7 sodium channel comprises 1988 amino acids (according to NM_002977.2) organized into four domains (D1–D4), each with six transmembrane segments (S1–S6). Segments S4 are probably the voltage-sensors and are characterized by a series of positively charged amino acids at every third position (<xref ref-type="fig" rid="fig3-1358863X11422584">Figure 3</xref>).<sup><xref ref-type="bibr" rid="bibr15-1358863X11422584">15</xref></sup> The amino acid 875 affected by our patient’s mutation is part of the fifth transmembrane span in D2. To date, around 20 mutations have been identified in patients with primary erythromelalgia (<xref ref-type="table" rid="table2-1358863X11422584">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr16-1358863X11422584">16</xref>–<xref ref-type="bibr" rid="bibr27-1358863X11422584">27</xref></sup> Most of the mutations identified so far cluster within D1 and D2 of the protein. Some mutations are located in the cytoplasmic linkers, and others, like the one reported here, are located at the transmembrane domains of the channel.<sup><xref ref-type="bibr" rid="bibr19-1358863X11422584">19</xref>,<xref ref-type="bibr" rid="bibr28-1358863X11422584">28</xref></sup> Functionally, most of the studied primary erythromelalgia-related mutations were shown to produce a hyperpolarizing shift in activation and slow deactivation and enhance the channel response to small depolarizing stimuli; changes that can confer hyperexcitability of cells harboring these channels.<sup><xref ref-type="bibr" rid="bibr15-1358863X11422584">15</xref></sup> While the alteration of the sympathetic neurons’ function leads to the microvascular symptoms, the alteration of the nociceptive neurons’ function results in severe burning pain, characterizing erythromelalgia.<sup><xref ref-type="bibr" rid="bibr10-1358863X11422584">10</xref></sup></p>
<fig id="fig3-1358863X11422584" position="float">
<label>Figure 3.</label>
<caption>
<p>Na(v)1.7 sodium channel structure.</p>
</caption>
<graphic xlink:href="10.1177_1358863X11422584-fig3.tif"/>
</fig>
<table-wrap id="table2-1358863X11422584" position="float">
<label>Table 2.</label>
<caption>
<p>Sodium channel missense mutations at different nucleotide positions and resulting disorders</p>
</caption>
<graphic alternate-form-of="table2-1358863X11422584" xlink:href="10.1177_1358863X11422584-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">PE-related missense mutation</th>
<th align="left">Nucleotide position (NM_002977.2)</th>
<th align="left">Disorder</th>
<th align="left">Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q10R</td>
<td>29A&gt;G</td>
<td>PE</td>
<td>16</td>
</tr>
<tr>
<td>I136V</td>
<td>406A&gt;G</td>
<td>PE</td>
<td>17</td>
</tr>
<tr>
<td>S211P</td>
<td>631T&gt;C</td>
<td>PE</td>
<td>18</td>
</tr>
<tr>
<td>F216S</td>
<td>647T&gt;C</td>
<td>PE</td>
<td>19</td>
</tr>
<tr>
<td>I234T</td>
<td>701T&gt;C</td>
<td>PE</td>
<td>20</td>
</tr>
<tr>
<td>S241T</td>
<td>721T&gt;A</td>
<td>PE</td>
<td>21</td>
</tr>
<tr>
<td>N395K</td>
<td>1185C&gt;A</td>
<td>PE</td>
<td>19</td>
</tr>
<tr>
<td>N395K</td>
<td>1185C&gt;G</td>
<td>PE</td>
<td/>
</tr>
<tr>
<td>V400M</td>
<td>1198G&gt;A</td>
<td>E, carbamazepine-responsive</td>
<td>22</td>
</tr>
<tr>
<td>P610T</td>
<td>1828C&gt;A</td>
<td>PE</td>
<td>19</td>
</tr>
<tr>
<td>L823R</td>
<td>2468T&gt;G</td>
<td>PE</td>
<td>23</td>
</tr>
<tr>
<td>I848T</td>
<td>2543T&gt;C</td>
<td>PE</td>
<td>19</td>
</tr>
<tr>
<td>L858F</td>
<td>2572C&gt;T</td>
<td>PE</td>
<td>19</td>
</tr>
<tr>
<td>L858H</td>
<td>2573T&gt;A</td>
<td>PE</td>
<td/>
</tr>
<tr>
<td>A863P</td>
<td>2587G&gt;C</td>
<td>PE</td>
<td>24</td>
</tr>
<tr>
<td>V872G</td>
<td>2615T&gt;G</td>
<td>PE</td>
<td>25</td>
</tr>
<tr>
<td><bold><italic>Q875E</italic></bold></td>
<td><bold><italic>2623C&gt;G</italic></bold></td>
<td><bold><italic>PE</italic></bold></td>
<td><bold><italic>Our case</italic></bold></td>
</tr>
<tr>
<td>P1308L</td>
<td>3923C&gt;T</td>
<td>PE</td>
<td>26</td>
</tr>
<tr>
<td>F1449V</td>
<td>4345T&gt;G</td>
<td>PE</td>
<td>11</td>
</tr>
<tr>
<td>A1632E</td>
<td>4895C&gt;A</td>
<td>PE / paroxysmal extreme pain disorder</td>
<td>27</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1358863X11422584">
<p>P, primary; E, erythromelalgia.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Despite an increase blood flow (as measured with laser Doppler), there is local hypoxia that can be reflected by low TCPO<sub>2</sub> values, which might be explained by arteriovenous shunting at a microvascular level.<sup><xref ref-type="bibr" rid="bibr29-1358863X11422584">29</xref></sup> Unlike the primary type, secondary type pathophysiology is poorly understood and thought to be due to neuropathological and microvascular functional changes caused by the underlying condition.<sup><xref ref-type="bibr" rid="bibr30-1358863X11422584">30</xref></sup></p>
<p>Since there is no diagnostic test for erythromelalgia, a very good history and physical exam are crucial for the diagnosis. Differential diagnoses may include cellulitis, erysipelas, dermatitis, osteomyelitis, complex regional pain syndrome, systemic lupus erythematosus (SLE), peripheral neuropathy, arterial or venous insufficiency, and gout.<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref></sup> Vascular laboratory studies might reveal normal arterial Doppler signals, increased temperature and laser Doppler values in the presence of low TCPO<sub>2</sub>.<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref></sup> Autonomic reflex screen testing can be abnormal with small fiber disease. Genetic testing can be helpful in making the diagnosis of the primary type.<sup><xref ref-type="bibr" rid="bibr10-1358863X11422584">10</xref>,<xref ref-type="bibr" rid="bibr11-1358863X11422584">11</xref></sup> There are no general guidelines on testing for <italic>SCN9A</italic> mutations. Testing can be considered in young patients with positive family history when secondary etiologies are less likely. Sometimes genetic testing is requested by the patient. Testing can also have some impact on family planning since the probability to inherit the mutation and having a child with the same disease is 50%. Genetic testing to prove inherited rather than secondary erythromelalgia might also limit repeated extensive and expensive work up looking for other underlying etiologies. So far, there is no specific therapy (e.g. Nav1.7 channel blockers) but once they are available, this will be a promising therapeutic approach for patients with positive mutations.</p>
<p>Management is very difficult and should follow a multidisciplinary approach. There is no single effective treatment for erythromelalgia. Management includes patient education, avoiding aggravating factors, cooling techniques, controlling secondary and underlying factors, and selective medications.<sup><xref ref-type="bibr" rid="bibr31-1358863X11422584">31</xref></sup> Aspirin is more effective in patients with secondary erythromelalgia caused by myeloproliferative disorders.<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref>,<xref ref-type="bibr" rid="bibr31-1358863X11422584">31</xref></sup> Sodium nitroprusside may be helpful in children.<sup><xref ref-type="bibr" rid="bibr32-1358863X11422584">32</xref></sup> Vasoactive drugs including β-blockers, magnesium, prostaglandin E1, iloprost (prostacyclin analog), and ergot alkaloids have been reported to relieve symptoms.<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref>,<xref ref-type="bibr" rid="bibr31-1358863X11422584">31</xref></sup> There are conflicting reports about the role of calcium channel blockers.<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref></sup> Neuroactive drugs including SSRIs, tricyclic antidepressants, gabapentin, pregabalin and benzodiazepines have also been reported to have some efficacy.<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref>,<xref ref-type="bibr" rid="bibr31-1358863X11422584">31</xref></sup> NSAIDs and other types of analgesics and narcotics administered by different routes can be carefully used for pain control.<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref></sup> Surgical procedures including sympathectomy and sympathetic nerve block can be tried in intractable cases.<sup><xref ref-type="bibr" rid="bibr12-1358863X11422584">12</xref>,<xref ref-type="bibr" rid="bibr33-1358863X11422584">33</xref></sup> There has been conflicting evidence for other therapies including acupuncture, biofeedback, hypnosis, and magnets.<sup><xref ref-type="bibr" rid="bibr19-1358863X11422584">19</xref>,<xref ref-type="bibr" rid="bibr34-1358863X11422584">34</xref></sup></p>
<p>Our patient had severe progressive primary erythromelalgia caused by a new de novo heterozygous missense mutation (c.2623C&gt;G) of the <italic>SCN9A</italic> gene which substitutes glutamine 875 by glutamic acid (p.Q875E). To our knowledge, this mutation has not been previously reported in the literature. Since the mutation occurred de novo and the residue at position 875 of the protein was highly conserved, this mutation is mostly the cause of her disease. Moreover, it was predicted to be damaging based on in-silico analysis using PolyPhen and Mutation Taster. We propose that p.Q875E, in line with the mutations described so far, is likely to cause a gain-of-function in the <italic>SCN9A</italic> gene. Brachydactyly is unreported in primary erythromelalgia and it may represent an unrelated finding. Short stature and growth hormone deficiency is not frequently reported in primary erythromelalgia. However, erythromelalgia, growth hormone deficiency, and hypertension responsive to recombinant human growth hormone have been reported by Cimaz et al. in 2001. It remains unknown whether or not this could represent a specific feature of this novel mutation.<sup><xref ref-type="bibr" rid="bibr35-1358863X11422584">35</xref></sup> Her disease exacerbation during puberty might implicate a hormonal role in the disease pathophysiology.</p>
<p>Pain-associated channelopathies represent an emerging field, and their discovery and understanding will pave the way for new management options.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<p>The authors declare that there is no conflict of interest.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1358863X11422584">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitchell</surname><given-names>SW</given-names></name>
</person-group>. <article-title>On a rare vaso-motor neurosis of the extremities and on the maladies with which it may be confounded</article-title>. <source>Am J Med Sci</source> <year>1878</year>; <volume>76</volume>: <fpage>17</fpage>.</citation>
</ref>
<ref id="bibr2-1358863X11422584">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Graves</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Clinical lectures on the practice of medicine</article-title>. <publisher-loc>Dublin</publisher-loc>: <publisher-name>Fannin</publisher-name>, <year>1834</year>.</citation>
</ref>
<ref id="bibr3-1358863X11422584">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>LA</given-names></name>
<name><surname>Allen</surname><given-names>EV</given-names></name>
</person-group>. <article-title>Erythermalgia (erythromelalgia), of the extremities: a syndrome characterized by redness, heat and pain</article-title>. <source>Am Heart J</source> <year>1938</year>; <volume>16</volume>: <fpage>175</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr4-1358863X11422584">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>T</given-names></name>
</person-group>. <article-title>Clinical observation and experiments relating to burning pain in extremities and to so-called ‘erythromelalgia’ in particular</article-title>. <source>Clin Sci</source> <year>1933</year>; <volume>1</volume>: <fpage>175</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr5-1358863X11422584">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albuquerque</surname><given-names>LG</given-names></name>
<name><surname>França</surname><given-names>ER</given-names></name>
<name><surname>Kozmhinsky</surname><given-names>V</given-names></name>
<name><surname>Querino</surname><given-names>MC</given-names></name>
<name><surname>Morais</surname><given-names>AG</given-names></name>
</person-group>. <article-title>Primary erythromelalgia: case report</article-title>. <source>An Bras Dermatol</source> <year>2011</year>; <volume>86</volume>: <fpage>131</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr6-1358863X11422584">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>MD</given-names></name>
<name><surname>O’Fallon</surname><given-names>WM</given-names></name>
<name><surname>Rogers</surname><given-names>RS</given-names></name>
<name><surname>Rooke</surname><given-names>TW</given-names></name>
</person-group>. <article-title>Natural history of erythromelalgia: presentation and outcome in 168 patients</article-title>. <source>Arch Dermatol</source> <year>2000</year>; <volume>136</volume>: <fpage>330</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr7-1358863X11422584">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mørk</surname><given-names>C</given-names></name>
<name><surname>Kalgaard</surname><given-names>OM</given-names></name>
<name><surname>Kvernebo</surname><given-names>K</given-names></name>
</person-group>. <article-title>Erythromelalgia: a clinical study of 102 cases (abstract)</article-title>. <source>Australas J Dermatol</source> <year>1997</year>; <volume>38</volume>(<issue>suppl 2</issue>): <fpage>50</fpage>.</citation>
</ref>
<ref id="bibr8-1358863X11422584">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kvernebo</surname><given-names>K</given-names></name>
</person-group>. <article-title>Erythromelalgia: a condition caused by microvascular arteriovenous shunting</article-title>. <source>VASA-J Vasc Dis Suppl</source> <year>1998</year>; <volume>51</volume>: <fpage>1</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr9-1358863X11422584">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reed</surname><given-names>KB</given-names></name>
<name><surname>Davis</surname><given-names>MD</given-names></name>
</person-group>. <article-title>Incidence of erythromelalgia: a population-based study in Olmsted County, Minnesota</article-title>. <source>J Eur Acad Dermatol Venereol</source> <year>2009</year>; <volume>23</volume>: <fpage>13</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr10-1358863X11422584">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Novella</surname><given-names>SP</given-names></name>
<name><surname>Hisama</surname><given-names>FM</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Waxman</surname><given-names>SG</given-names></name>
</person-group>. <article-title>A case of inherited erythromelalgia</article-title>. <source>Nat Clin Pract Neurol</source> <year>2007</year>; <volume>3</volume>: <fpage>229</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr11-1358863X11422584">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Rush</surname><given-names>AM</given-names></name>
<name><surname>Cummins</surname><given-names>TR</given-names></name>
<etal/></person-group>. <article-title>Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons</article-title>. <source>Brain</source> <year>2005</year>; <volume>128</volume>(<issue>Pt 8</issue>): <fpage>1847</fpage>–<lpage>1854</lpage>.</citation>
</ref>
<ref id="bibr12-1358863X11422584">
<label>12.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>MP</given-names></name>
<name><surname>Rooke</surname><given-names>TW</given-names></name>
</person-group>. <article-title>Erythromelalgia</article-title>. In: <person-group person-group-type="editor">
<name><surname>Creager</surname><given-names>MA</given-names></name>
<name><surname>Dzau</surname><given-names>VJ</given-names></name>
<name><surname>Loscalzo</surname><given-names>J</given-names></name>
</person-group> (eds) <source>Vascular medicine: a companion to Braunwald’s heart disease</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Elsevier, Inc.</publisher-name>, <year>2006</year>, p.<fpage>711</fpage>–<lpage>721</lpage>.</citation>
</ref>
<ref id="bibr13-1358863X11422584">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Latessa</surname><given-names>V</given-names></name>
</person-group>. <article-title>Erythromelalgia: a rare microvascular disease</article-title>. <source>J Vasc Nurs</source> <year>2010</year>; <volume>28</volume>: <fpage>67</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr14-1358863X11422584">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sangameswaran</surname><given-names>LM</given-names></name>
<name><surname>Fish</surname><given-names>BD</given-names></name>
<name><surname>Koch</surname><given-names>DK</given-names></name>
<etal/></person-group>. <article-title>A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia</article-title>. <source>J Biol Chem</source> <year>1997</year>; <volume>272</volume>: <fpage>14,805</fpage>–<lpage>14,809</lpage>.</citation>
</ref>
<ref id="bibr15-1358863X11422584">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dabby</surname><given-names>R</given-names></name>
<name><surname>Sadeh</surname><given-names>M</given-names></name>
<name><surname>Gilad</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Chronic non-paroxysmal neuropathic pain – novel phenotype of mutation in the sodium channel</article-title>
<comment>SCN9A gene</comment>. <source>J Neurol Sci</source> <year>2011</year>; <volume>301</volume>: <fpage>90</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr16-1358863X11422584">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>C</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Lin</surname><given-names>Z</given-names></name>
<etal/></person-group>. <article-title>Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation</article-title>. <source>Brain</source> <year>2009</year>; <volume>132</volume>(<issue>Pt 7</issue>): <fpage>1711</fpage>–<lpage>1722</lpage>.</citation>
</ref>
<ref id="bibr17-1358863X11422584">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>MJ</given-names></name>
<name><surname>Yu</surname><given-names>HS</given-names></name>
<name><surname>Hsieh</surname><given-names>ST</given-names></name>
<name><surname>Stephenson</surname><given-names>DA</given-names></name>
<name><surname>Lu</surname><given-names>CJ</given-names></name>
<name><surname>Yang</surname><given-names>CC</given-names></name>
</person-group>. <article-title>Characterization of a familial case with primary erythromelalgia from Taiwan</article-title>. <source>J Neurol</source> <year>2007</year>; <volume>254</volume>: <fpage>210</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr18-1358863X11422584">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Estacion</surname><given-names>M</given-names></name>
<name><surname>Choi</surname><given-names>JS</given-names></name>
<name><surname>Eastman</surname><given-names>EM</given-names></name>
<etal/></person-group>. <article-title>Can robots patch-clamp as well as humans? Characterization of a novel sodium channel mutation</article-title>. <source>J Physiol</source> <year>2010</year>; <volume>588</volume>: <fpage>1915</fpage>–<lpage>1927</lpage>.</citation>
</ref>
<ref id="bibr19-1358863X11422584">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drenth</surname><given-names>JP</given-names></name>
<name><surname>Waxman</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders</article-title>. <source>J Clin Invest</source> <year>2007</year>; <volume>117</volume>: <fpage>3603</fpage>–<lpage>3609</lpage>.</citation>
</ref>
<ref id="bibr20-1358863X11422584">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahn</surname><given-names>HS</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Cox</surname><given-names>JJ</given-names></name>
<etal/></person-group>. <article-title>A new Nav1.7 sodium channel mutation I234T in a child with severe pain</article-title>. <source>Eur J Pain</source> <year>2010</year>; <volume>14</volume>: <fpage>944</fpage>–<lpage>950</lpage>.</citation>
</ref>
<ref id="bibr21-1358863X11422584">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lampert</surname><given-names>A</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Tyrrell</surname><given-names>L</given-names></name>
<name><surname>Waxman</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Size matters: erythromelalgia mutation S241T in Nav1.7 alters channel gating</article-title>. <source>J Biol Chem</source> <year>2006</year>; <volume>281</volume>: <fpage>36,029</fpage>–<lpage>36,035</lpage>.</citation>
</ref>
<ref id="bibr22-1358863X11422584">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>TZ</given-names></name>
<name><surname>Gilmore</surname><given-names>ES</given-names></name>
<name><surname>Estacion</surname><given-names>M</given-names></name>
<name><surname>Eastman</surname><given-names>E</given-names></name>
</person-group>. <article-title>A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia</article-title>. <source>Ann Neurol</source> <year>2009</year>; <volume>65</volume>: <fpage>733</fpage>–<lpage>741</lpage>.</citation>
</ref>
<ref id="bibr23-1358863X11422584">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lampert</surname><given-names>A</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Eastman</surname><given-names>EM</given-names></name>
<etal/></person-group>. <article-title>Erythromelalgia mutation L823R shifts activation and inactivation of threshold sodium channel Nav1.7 to hyperpolarized potentials</article-title>. <source>Biochem Biophys Res Commun</source> <year>2009</year>; <volume>390</volume>: <fpage>319</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr24-1358863X11422584">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harty</surname><given-names>TP</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Tyrrell</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Na(V)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons</article-title>. <source>J Neurosci</source> <year>2006</year>; <volume>26</volume>: <fpage>12,566</fpage>–<lpage>12,575</lpage>.</citation>
</ref>
<ref id="bibr25-1358863X11422584">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choi</surname><given-names>JS</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<etal/></person-group>. <article-title>Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off</article-title>. <source>Exp Neurol</source> <year>2009</year>; <volume>216</volume>: <fpage>383</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr26-1358863X11422584">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>X</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Tyrrell</surname><given-names>L</given-names></name>
<name><surname>Wright</surname><given-names>DA</given-names></name>
<name><surname>Fischer</surname><given-names>TZ</given-names></name>
<name><surname>Waxman</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na V 1.7 produce distinct pain disorders</article-title>. <source>Mol Pain</source> <year>2010</year>; <volume>6</volume>: <fpage>24</fpage>.</citation>
</ref>
<ref id="bibr27-1358863X11422584">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Estacion</surname><given-names>M</given-names></name>
<name><surname>Dib-Hajj</surname><given-names>SD</given-names></name>
<name><surname>Benke</surname><given-names>PJ</given-names></name>
<etal/></person-group>. <article-title>NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders</article-title>. <source>J Neurosci</source> <year>2008</year>; <volume>28</volume>: <fpage>11,079</fpage>–<lpage>11,088</lpage>.</citation>
</ref>
<ref id="bibr28-1358863X11422584">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klugbauer</surname><given-names>N</given-names></name>
<name><surname>Lacinova</surname><given-names>L</given-names></name>
<name><surname>Flockerzi</surname><given-names>V</given-names></name>
<name><surname>Hofmann</surname><given-names>F</given-names></name>
</person-group>. <article-title>Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells</article-title>. <source>EMBO J</source> <year>1995</year>; <volume>14</volume>: <fpage>1084</fpage>–<lpage>1090</lpage>.</citation>
</ref>
<ref id="bibr29-1358863X11422584">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mørk</surname><given-names>C</given-names></name>
<name><surname>Kvernebo</surname><given-names>K</given-names></name>
<name><surname>Asker</surname><given-names>CL</given-names></name>
<name><surname>Salerud</surname><given-names>EG</given-names></name>
</person-group>. <article-title>Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism</article-title>. <source>J Invest Dermatol</source> <year>2002</year>; <volume>119</volume>: <fpage>949</fpage>–<lpage>953</lpage>.</citation>
</ref>
<ref id="bibr30-1358863X11422584">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Erythromelalgia: new theories and new therapies</article-title>. <source>J Am Acad Dermatol</source> <year>2000</year>; <volume>43</volume>(<issue>5 Pt 1</issue>): <fpage>841</fpage>–<lpage>847</lpage>.</citation>
</ref>
<ref id="bibr31-1358863X11422584">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>MD</given-names></name>
<name><surname>Rooke</surname><given-names>T</given-names></name>
</person-group>. <article-title>Erythromelalgia</article-title>. <source>Curr Treat Options Cardiovasc Med</source> <year>2006</year>; <volume>8</volume>: <fpage>153</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr32-1358863X11422584">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stone</surname><given-names>JD</given-names></name>
<name><surname>Rivey</surname><given-names>MP</given-names></name>
<name><surname>Allington</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Nitroprusside treatment of erythromelalgia in an adolescent female</article-title>. <source>Ann Pharmacother</source> <year>1997</year>; <volume>31</volume>: <fpage>590</fpage>–<lpage>592</lpage>.</citation>
</ref>
<ref id="bibr33-1358863X11422584">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>WH</given-names></name>
<name><surname>Li</surname><given-names>LF</given-names></name>
<etal/></person-group>. <article-title>Long-term remission of primary erythermalgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy</article-title>. <source>Eur J Dermatol</source> <year>2010</year>; <volume>20</volume>: <fpage>763</fpage>–<lpage>767</lpage>.</citation>
</ref>
<ref id="bibr34-1358863X11422584">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chakravarty</surname><given-names>K</given-names></name>
<name><surname>Pharoah</surname><given-names>PD</given-names></name>
<name><surname>Scott</surname><given-names>DG</given-names></name>
<name><surname>Barker</surname><given-names>S</given-names></name>
</person-group>. <article-title>Erythromelalgia—the role of hypnotherapy</article-title>. <source>Postgrad Med J</source> <year>1992</year>; <volume>68</volume>: <fpage>44</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr35-1358863X11422584">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cimaz</surname><given-names>R</given-names></name>
<name><surname>Rusconi</surname><given-names>R</given-names></name>
<name><surname>Fossali</surname><given-names>E</given-names></name>
<name><surname>Careddu</surname><given-names>P</given-names></name>
</person-group>. <article-title>Unexpected healing of cutaneous ulcers in a short child</article-title>. <source>Lancet</source> <year>2001</year>; <volume>358</volume>: <fpage>211</fpage>–<lpage>212</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>